Articles related to MOOD DISORDERS

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.

The Tardive Dyskinesia Impact Scale showed high discrimination and precision across physical function and socioemotional domains in pooled data from 388 patients in the KINECT 3 and KINECT 4 valbenazine trials.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

Algorithm-guided treatment was associated with improved remission rates in 5 of 7 randomized trials of major depressive disorder, though heterogeneity in protocols and outcome measures limited direct comparability.

“Health care systems should recruit more trained psychologists and offer combinations of evidence-based pharmacotherapy and psychotherapy to patients with mood disorder, especially with suicide risk in resource-limited settings.” — Study authors, Journal of Psychiatric Research

Sleep neurologist emphasizes that waking up happy requires intentional planning: adequate sleep duration, circadian rhythm alignment, consistent wake times, and meaningful daily purpose create the foundation for morning well-being.